At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 351 enrolled
Drug / intervention
Takeda's Tetravalent Dengue Vaccine Candidate (TDV) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Double-Blind, Randomized, Controlled Trial to Assess the Safety and Immunogenicity of a Tetravalent Dengue Vaccine With Two Different Serotype 2 Potencies in an Adult Population in Singapore
In Brief
A Phase 2 clinical trial evaluating Takeda's Tetravalent Dengue Vaccine Candidate (TDV) and Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV) for Dengue Fever. Completed, enrolled 351 participants across 3 sites.
Detailed Summary
The purpose of this study is to assess the post-vaccination neutralizing antibody response against each dengue serotype by vaccine group.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDengue Fever
CountriesSingapore
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 2015
Enrollment StartJun 2015
Primary CompletionSep 2017
TodayJul 2026
First PostedApr 23, 2015
Enrollment StartJun 3, 2015
Primary CompletionSep 18, 2017
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 11.2 years ago
Interventions
Takeda's Tetravalent Dengue Vaccine Candidate (TDV)biological
TDV subcutaneous injection
Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV)biological
High-dose TDV subcutaneous injection